跳至主要内容
临床试验/JPRN-jRCT2031180066
JPRN-jRCT2031180066进行中(未招募)1 期

Prospective study of Romiplostim for rapid platelet recovery after cord blood transplantation, phase 1 - PROMPT-1

Chiba Shigeru0 个研究点目标入组 6 人开始时间: 2018年12月27日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16age old 至 65age old(—)
性别
All

入选标准

  • 1. Preliminary inclusion criteria
  • 1) Patients with AML (blast < 5%), ALL (blast < 5%), MDS (blast < 5%), or NHL (complete response or partial response)
  • 2) Patients 16 to 65 years of age
  • 3) Patients who do not have HLA antigen-matched (6/6) appropriate related donors
  • 4) Patients who do not have HLA allele-matched (8/8) unrelated donors.
  • 5) Patients with ECOG of 0, 1, or 2
  • 6) Patients without severe dysfunction in the heart, the lung, the liver, and the kidney
  • (a) ejection fraction >= 40%
  • (b) SaO2 (or SpO2) >= 94%
  • (c) %VC >= 70%, and FEV1.0% >= 70%
  • (d) total bilirubin < x1.5 of the upper limit
  • (e) ALT < x3 of the upper limit
  • (f) AST < x3 of the upper limit
  • (g) creatinine < 2.0 mg/dL
  • 7) Patients who gave written informed consent
  • 2. Secondary inclusion criteria
  • 1) SaO2 (or SpO2) >= 94%
  • 2) total bilirubin < x1.5 of the upper limit
  • 3) ALT < x3 of the upper limit
  • 4) AST < x3 of the upper limit
  • 5) creatinine < 2.0 mg/d

排除标准

  • 1. Preliminary exclusion criteria
  • 1) Patients with anti-HLA antibody
  • 2) Patients with uncontrollable psychological complications
  • 3) Patients with active double cancer
  • 4) Patients with uncontrollable active infection
  • 5) Patients with bone marrow fibrosis (reticulin grade >= 2)
  • 6) Patients with prior history of allogeneic hematopoietic transplantation
  • 7) Patients with severe cardiac complications
  • 8) Patient with prior thrombotic history or with predisposing factors to thrombosis
  • 9) Patients with positive for HIV antibody, HBs antigen, or HCV-RNA
  • 10) Patients with uncontrollable diabetes mellitus
  • 11) Patients with uncontrollable hypertension
  • 12) Patients who were enrolled to other clinical trials within 3 months
  • 13) Patients with prior history of TPO-R administration
  • 14) Patients with hypersensitivity to recombinant protein derived from E-coli
  • 15) Pregnant women, patients during lactation, or patients who deny anticonception
  • 16) Patients who are judged inappropriate by investigators
  • 2. Secondary exclusion criteria
  • 1) Patients who are judged inappropriate by investigators

研究者

发起方
Chiba Shigeru

相似试验